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The Cytochrome P450 2D6 (CYP2D6) gene, currently one of the most extensively 
characterized P450 isoenzymes, has an intrinsic role in the metabolism of 25% of all clinically 
relevant drugs, including tricyclic antidepressants, beta blockers, and opiates. CYP2D6 
enzyme function is known to vary depending on individual genotypes. Significant racial 
differences in site and frequency of genetic polymorphisms, cause differential enzyme activity 
profiles among worldwide populations.  
The phenotypic consequences resulting in the presence of genetic polymorphisms critically 
affects the biotransformation of CYP2D6 substrates either in an increase, decrease, or 
complete loss of enzymatic activity. In this sense, the phenotype-genotype refers to the 
relationship between the measurement of the actual hydroxylating capacity (metabolic 
phenotype) and the estimation based on the activity score of the alleles. In the case of poor 
metabolizers, the expected correlation with the metabolic phenotype is practically achieved 
as the allelic variants result in an enzyme with null activity; either by deletion of part of the 
gene, splicing defects or displacement of the reading frame. Conversely, normal or 
intermediate metabolizers do not always correspond, omitting considerations for 
misclassification, additional environmental factors such as concomitant pharmacological 
treatment, disease or dietary interactions can intervene in the actual metabolic activity 
producing a phenocopy. 
While CYP2D6 allele and phenotype frequencies have been extensively studied, currently, 
very little ethnically specific data is available regarding admixed populations in the Central 
American, East African and South Pacific region, including Guatemala, Kenya, and Vanuatu. 
Moreover, to our knowledge, P450 genotyping information is not yet available for the 
Guatemalan population in general or self-defined ethnically distinct groups. Our study 
populations are the product of complex admixture; thus, it is of interest to evaluate the 
interethnic variability of polymorphisms with pharmacogenetic relevance, including CYP2D6. 
Given the scarceness of CYP2D6 related data in these populations, the purpose of this study 
was to perform a pharmacogenomic analysis of the Guatemalan, Kenyan and Ni-Vanuatu 
populations using PCR gene amplification coupled with Sanger sequencing-based SNP 
genotyping. Additionally, ddPCR based methodologies were used to verify detected copy 
number variations, including gene deletions, multiplication, and tandem arrangement genes. 
The activity score system model A was used to determine CYP2D6 phenotype assignments 
from genotype data. And ultimately characterize the enzymatic properties of novel CYP2D6 
variant proteins expressed in 293FT cells in vitro by measuring Dextromethorphan O-
demethylation activity, a drug classified as a synthetic analog of codeine and a commonly used 
probe substrate for determining CYP2D6 activity, in which CYP2D6 primarily mediates the 
formation of its metabolite dextrorphan from dextromethorphan via O-demethylation with a 
minor contribution from CYP3A4. Moreover, in an attempt to elucidate the molecular causes 
and structural alterations rationalizing the observed functional effects fitting to each variant, 
a 3D structural docking analysis was performed in which the molecular interactions between 
CYP2D6 novel variants and dextromethorphan were evaluated.  
This study revealed significant differences in the frequency CYP2D6 alleles and the resulting 
metabolic phenotypes among the study populations. Being a marked prevalence of functional 
alleles in all studied populations, with the majority of population subjects classified as normal 
metabolizers, with frequencies exceeding 60% in all populations (Guatemala 69.4%, Vanuatu 
89.2%, and Kenya 64.1%,). Correspondingly, a low frequency for decreased function defining 
genotypes was observed in the Guatemalan and Ni-Vanuatu population, while approximately 
36% of Kenyan subjects presented substrate-dependent reduced function alleles. These data 
were consistent with previous studies, in which approximately 50% of CYPD6 alleles found 
were normal function in Americans, Hispanics, Africans, and African Americans. while 
Oceanians are known to exhibit only full-functional variants with frequencies of wild-type 
CYP2D6 of up to 85%, concurring with the findings for the Ni-Vanuatu population 
Accordingly, the main allelic frequencies in Guatemala and extrapolated phenotypes are in 
accordance with Amerindian populations found in North and Central America but differ 
considerably from those in South America and the Caribbean. These differences are considered 
in part to be caused by the higher degree of African admixture in which genotypic 
characteristics are more profoundly influenced by polymorphisms native to this region in which 
metabolizer status has been observed to be influenced in great part by the high frequency of 
the decreased function alleles. Whereas the allelic frequencies and extrapolated phenotypes 
for Kenya and Vanuatu do not notably differ from populations found in their respective regions. 
Notably, the A449D polymorphism was detected in the Guatemalan population, with a 
frequency of approximately 5%; this polymorphism has been reported only once before in a 
study comprising three populations of Mexican Amerindians with an approximate frequency of 
4%, this finding further supports anthropological theories of ancient migratory patterns 
between neighboring Amerindian populations.  
Additionally, a total of 17 novel polymorphism were found (Guatemala: A449D, Y335C, M279K, 
V307I, P354S, A165V, D337N. R329C, S304L, R344X; Vanuatu: V104A, P171L, R269Q, 
G306R, V402L, and Kenya: L203F, I339L, H376R) The analysis of novel non-synonymous 
SNPs identified amongst Guatemalan subjects in respects to the impact of their amino acid 
substitutions on protein structure/function revealed that A449D and  P354S, are estimated 
to detrimentally affect enzymatic function and resultant metabolic activity. While amongst the 
Ni-Vanuatu and Kenyan functionally characterized variants, 3 novel variants (P171L, G306R, 
V402L) and 3 variant containing alleles (L203F, I339L, H376R) respectively, showed 
significantly reduced intrinsic clearance compared to that of wild-type CYP2D6.1.  
The A449D a variant found as an additional SNP located in exon 9 of the CYP2D6*4 allele, is 
a substitution of hydrophobic alanine with neutral aspartic acid in the L helix. This change 
would decrease the hydrophobicity and integrity of this helix causing it to shift outwards and 
gain additional interactions with substrate recognition sites (SRS) and the active cavity 
indirectly influencing heme incorporation.  
Located in the K helix, the P354S substitution would be expected to affect this highly 
conserved turn motif by the presence of additional heme interactions with SRS-1 member F120, 
involved in substrate recognition and binding while also lacking interactions with the E334 
residue. Taken together, these changes could perturb the active site and influence heme 
incorporation, resulting in a protein with low substrate affinity and enzyme efficiency. 
3D structural analysis further revealed that variants with reduced enzymatic activity showed 
that the amino acid substitutions present caused shifts in molecular interactions resulting in 
structural changes involving access channels, the heme binding site, and substrate recognition 
sites. Correspondingly, the determination of microsomal P450 contents by CO difference 
spectroscopy revealed that possible structural differences affecting heme incorporation in the 
G306R variant and L203F containing allele as they did not show an increase in absorbance 
near 450nm, signifying the amount of active holoprotein was insufficient for detection.  
Amino acid substitutions in the conserved G306, located in the N-terminus of the I helix and 
present in the SRS-4, can lead to increases in the side-chain volume introducing steric clashes 
and thus obstruct the binding mode. Several structural changes were observed in the K1 
variant, harboring the L203F, and CYP2D6*2 (R296C and S486T) substitutions, including a 
decrease in distance between the F203 and amino acids located in the vicinity of the solvent 
channel hydrophilic bottleneck. These changes, in turn, lead to the decreased interactions 
with substrate recognition sites and changes in heme binding patterns that might result in a 
structurally unstable holoprotein and thus affect overall function. 
Moreover, the V402L variant and H376R containing novel allele K3, which exhibited 
significantly decreased activity but detectable P450 content, both showed interactions that 
may result in impediments with substrate recognition. The V402L substitution found in the K' 
helix was seen to lack alkyl interactions between the substrate and substrate recognition site 
members. While at the same time causing several modified interactions involving heme. Taken 
together, these changes could generate continuous structural differences that would influence 
heme stereoselectivity, resulting in decreased substrate recognition. This theory is further 
supported by the considerable increase in Km observed for this variant, when compared to that 
of wild-type.  
Lastly, the K3 variant found to have the CYP2D6*10 substitution P34S alongside S486T and 
the novel H376R located in the β-strand and SRS-5. In this variant, substitution with the 
positively-charged polar arginine causes the β-strand to shift towards the external part of 
the protein, which in turn, causes several observed functionally important structural changes. 
These conformational changes could cause weak interaction with the active site and binding 
pocket. As a result, potentially leading to poor substrate recognition, which is consistent with 
these variants increased Km and Vmax. 
Allelic frequency determination, polymorphism identification in the CYPD6 gene and its 
subsequent evaluation over enzymatic activity performed in this study could aid in building 
population specific therapeutic profiles which in turn would benefit from taking ethnic 
differentiation and intra-ethnic variations into consideration. And as a result, improve 
therapeutic outcomes as well as supporting clinical pharmacologic profiling efforts. 
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胎児腎臓由来 293FT 細胞に発現させた組換え酵素を CYP2D6 の特異的基質薬物であるデキス
トロメトルファンと反応させ、その代謝物生成量から酵素機能変化を評価している。 
その結果、アミノ酸置換を誘発する新規遺伝子多型を 17 種類同定し、それらの機能変化を
詳細に明らかにした。特に、酵素活性が消失するバリアントに関しては、プリマキンを基質と
した場合、活性代謝物が体内で産生できずに薬効が得られない可能性が高い。したがって、本
論文は、遺伝的背景から個々に最適な抗マラリア薬の投与量を選択をする上で極めて重要な知
見を含んでいる。 
よって、本論文は博士（薬科学）の学位論文として合格と認める。 
